There are two approved drug and over 150 product candidates, which are being evaluated for the treatment of a variety of disease indications

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

 

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

Key Inclusions

• A detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, target disease indication(s), key therapeutic areas (oncological disorders, infectious diseases, genetic disorders, ophthalmic diseases, respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular disorders, dermatological disorders, and others),  type of RNAi molecule (siRNA, miRNA, shRNA, sshRNA and DNA), target genes, type of delivery system used, route of administration and special drug designations (if any).
• A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishment.
• An analysis of completed, ongoing and planned clinical studies for different types of RNAi molecules. The trials were analyzed on the basis of various relevant parameters, such as registration year, current status, phase of development, type of RNAi molecule, regional distribution of clinical trials and enrolled patient population.
• An in-depth analysis of the various patents that have been filed / granted related to RNAi therapeutics, since 2014. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.

 

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

• Key therapeutic areas

• Oncological disorders
• Infectious diseases
• Genetic disorders
• Ophthalmic disorders
• Hepatic disorders
• Respiratory disorders

 

• Type of RNAi molecule

• siRNA
• miRNA
• shRNA
• sshRNA
• DNA

 

• Route of administration

• Subcutaneous
• Intravenous
• Intradermal
• Intratumoral
• Intravitreal
• Oral
• Intramuscular

 

• Key geographical regions

• North America
• Europe
• Asia Pacific and the Rest of the World

 

• Leading Players

 

The RNAi Therapeutics Market (2nd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

• Quark Pharmaceuticals
• Alnylam Pharmaceuticals
• Dicerna Pharmaceuticals
• Souzhou Ribo Life Sciences
• Olix Pharmaceuticals
• Sirnaomics
• Ariz Precision Medicine
• Arrowhead Pharmaceuticals
• Gradalis
• Benitec Biopharma

 

Table of Contents

 

1.   PREFACE

 

2.   EXECUTIVE SUMMARY

 

3.   INTRODUCTION

 

4.   COMPETITIVE LANDSCAPE

 

5.   COMPANY COMPETITIVENESS ANALYSIS

 

6.   LATE STAGE RNAi THERAPEUTICS

 

7.   TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

 

8.   KEY THERAPEUTIC INDICATIONS

 

9.   CLINICAL TRIAL ANALYSIS

 

10. PATENT ANALYSIS

 

11. RECENT PARTNERSHIPS

 

12. FUNDING AND INVESTMENT ANALYSIS

 

13. PROMOTIONAL ANALYSIS

 

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

 

15. RNAi IN DIAGNOSTICS

 

16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS

 

17. SWOT ANALYSIS

 

18. CONCLUSION

 

19. INTERVIEW TRANSCRIPT(S)

 

20. APPENDIX 1: TABULATED DATA

 

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]